SGL Investment Advisors Inc. Acquires Shares of 2,668 Amgen Inc. (NASDAQ:AMGN)

SGL Investment Advisors Inc. bought a new position in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,668 shares of the medical research company’s stock, valued at approximately $790,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of Amgen during the third quarter worth about $25,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the 2nd quarter valued at about $30,000. Legacy Investment Solutions LLC bought a new stake in Amgen during the third quarter worth approximately $29,000. nVerses Capital LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $31,000. Finally, Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AMGN. UBS Group dropped their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Barclays raised their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 28th. Royal Bank of Canada lowered their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $323.05.

Amgen Stock Performance

AMGN opened at $272.58 on Monday. Amgen Inc. has a 1 year low of $257.80 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a market capitalization of $146.52 billion, a PE ratio of 34.90, a price-to-earnings-growth ratio of 3.08 and a beta of 0.55. The business has a fifty day simple moving average of $306.58 and a 200 day simple moving average of $315.86.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the company earned $4.96 EPS. The business’s revenue was up 23.2% on a year-over-year basis. Research analysts expect that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.30%. Amgen’s payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.